Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Advancements in Surgical Approaches for Gynecological Cancers

Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 11090

Share This Special Issue

Special Issue Editors

Dr. Anna Myriam Perrone

E-Mail Website
Guest Editor

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Interests: advancements in surgical techniques; surgical planning and decision-making; outcomes and challenges; patient-centered care
Special Issues, Collections and Topics in MDPI journals

Dr. Camelia Alexandra Coada

E-Mail Website
Guest Editor

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Interests: impact on long-term survival; multidisciplinary collaboration; current treatment challenges; molecular classification of tumors and their prognostic impact

Special Issue Information

Dear Colleagues,

Gynecological cancers, including ovarian, cervical, uterine, vulvar, and vaginal cancers, pose significant health challenges for women worldwide. With millions of women diagnosed each year, these cancers have a profound impact on both individual lives and public health. However, thanks to remarkable advancements in surgical approaches, there is newfound hope in the fight against gynecological cancers. Scientific breakthroughs and technological innovations have revolutionized the field of gynecologic oncology, offering safer, more precise, and minimally invasive surgical techniques. These advancements not only enhance diagnostic accuracy but also enable surgeons to tailor treatment plans and improve patient outcomes. The importance of these advancements in surgical approaches for gynecological cancers cannot be overstated, as they hold the potential to improve patient outcomes, enhance quality of life, and redefine the landscape of gynecologic oncology care.

We are pleased to invite you to contribute to this Special Issue titled “Advancements in Surgical Approaches for Gynecological Cancers” dedicated to the surgery of gynecological cancers, focusing on the advancements, challenges, and outcomes in this critical field.

It is well known that achieving complete surgical resection has paramount importance in the management of tumors, including gynecological cancers. The aim of this Special Issue is to provide a comprehensive overview of the evolving surgical techniques, novel approaches, and cutting-edge technologies that are revolutionizing the management of gynecological cancers. The articles included in this issue should emphasize the significance of thorough surgical planning, meticulous techniques, and multidisciplinary collaboration to ensure optimal cytoreduction and achieve negative surgical margins. By addressing the challenges and complexities associated with achieving complete surgery, this Special Issue aims to underscore the significance of this essential treatment modality in improving overall survival rates and disease-free intervals for patients with gynecological cancers. Through a comprehensive exploration of surgical advancements, techniques, and outcomes, this issue seeks to advance the knowledge and understanding of the integral role of complete surgery in the comprehensive management of gynecological malignancies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Impact of advancements in molecular and genetic classifications on therapeutic choices.

Evolving surgical techniques.

Role of neoadjuvant chemotherapy in surgical outcomes.

Minimally invasive surgical approaches.

Novel approaches.

Cutting-edge technologies.

Thorough surgical planning.

Meticulous techniques.

Application of current treatment guidelines.

Optimal cytoreduction and negative surgical margins.

Impact on overall survival and disease-free intervals.

We look forward to receiving your contributions.

Dr. Anna Myriam Perrone
Dr. Camelia Alexandra Coada
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

gynecological cancers
minimally invasive surgery
advancements in oncological treatments
challenges
survival outcomes
complete surgical resection
management
cytoreduction
negative surgical margins

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (9 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Other

19 pages, 1330 KB

Open AccessArticle

P-POSSUM Falls Short: Predicting Morbidity in Ovarian Cancer (OC) Cytoreductive Surgery

by Michail Sideris, Mark R. Brincat, Oleg Blyuss, Samuel George Oxley, Jacqueline Sia, Ashwin Kalra, Xia Wei, Caitlin T. Fierheller, Subhasheenee Ganesan, Rowan E. Miller, Fatima El-Khouly, Mevan Gooneratne, Tom Abbott, Ching Ling Pang, Parvesh Verma, Seema Shah, Alexandra Lawrence, Arjun Jeyarajah, Elly Brockbank, Saurabh Phadnis, James Dilley and Ranjit Manchanda Show full author list Hide full author list

Cancers 2025, 17(21), 3421; https://doi.org/10.3390/cancers17213421 (registering DOI) - 24 Oct 2025

Abstract

Objective: The P-POSSUM scale is widely used in predicting perioperative morbidity and mortality. Evidence on the performance of P-POSSUM in predicting outcomes after cytoreductive surgery (CRS) for ovarian cancer (OC) is limited. In this study, we assess how well P-POSSUM predicts morbidity in OC CRS and explore whether incorporating additional clinical variables can enhance its predictive accuracy. We retrospectively collected data on consecutive patients undergoing OC CRS within a tertiary gynaecologic oncology network. The collected information included demographic characteristics, P-POSSUM morbidity and mortality scores, Edmonton Frail Scale (EFS) scores, preoperative serum albumin levels, and observed 30-day postoperative morbidity and mortality, classified using the Clavien–Dindo (CD) scale. The predictive performance of P-POSSUM was evaluated using receiver operating characteristic (ROC) curves to calculate sensitivity and specificity. A stepwise regression analysis was then applied to identify additional variables that could improve model performance, incorporating preoperative covariates. The final model incorporated parameters chosen through bootstrap investigation of the model variability (stepAIC). Predicted versus observed morbidity was calibrated and performance compared between P-POSSUM and the final model. Results: Of 161 sequential OC patients, 95 (59%) underwent primary, 45 (28%) interval, and 21 (13%) delayed CRS. The mean age was 66.4 (95%CI: 60–75) and duration of surgery was 223 mins (95%CI: 142–279). Sixty-five (40.3%) patients had ≥1 postoperative complication. Two deaths were reported. Among the observed complications, 4 patients (6.1%) experienced CD4, 10 patients (15.3%) CD3, 38 patients (58.5%) CD2, and 11 patients (16.9%) CD1 events. The mean P-POSSUM-predicted morbidity and mortality were 59.5% (95%CI: 56.7–62.3%) and 5.86% (95%CI: 5.02–6.70%), respectively. The area under the curve (AUC) for P-POSSUM in predicting morbidity and mortality was 0.539 (p = 0.401) and 0.569 (p = 0.137), respectively. Given the small number of deaths, no robust conclusions regarding mortality are possible. EFS and BMI emerged as significant predictors of observed morbidity using a stepwise-model selection process. The AIC of this final model was 211.44. Our final model of PPOSSUM + EFS + BMI had AUC = 0.6551 (Delong’s Z = 1.8845, p-value = 0.05949). Conclusions: The P-POSSUM scale shows poor performance for predicting morbidity in OC CRS. New validated and accurate model(s) are necessary for predicting surgical morbidity. Our proposed model incorporates additional variables to improve P-POSSUM’s performance. This requires further development and validation. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Figure 1

11 pages, 1426 KB

Open AccessArticle

Trends in Surgical Outcomes and Overall Survival Among Women Undergoing Debulking Surgery for Advanced Ovarian Cancer in the U.S: Analysis of the National Cancer Database

by Kelly Lamiman, Michael Silver, Judy Hayek, Ryan Hanusek, Lea Sarmiento, Michael Kim, Nicole Goncalves and Ioannis Alagkiozidis

Cancers 2025, 17(17), 2884; https://doi.org/10.3390/cancers17172884 - 2 Sep 2025

Viewed by 1036

Abstract

Given the rising use of neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC), we sought to assess practice trends in overall survival (OS), complete gross resection (R0), and postoperative mortality following debulking surgery. The National Cancer Database (NCDB) was used to identify 34,982 stage IIIC and IV EOC patients between 2010 and 2017 who underwent surgery. Annual proportions of patients receiving IDS and PDS were calculated. Median OS was estimated using the Kaplan–Meier method. Joinpoint models were fitted to evaluate surgical trends. Statistics were performed using SPSS and Joinpoint. Of 34,982 patients, 10,460 (29.9%) underwent IDS. IDS patients were older, more likely to have stage IV disease, and more likely to be non-White. Median OS was higher in the PDS group (54 vs. 38.8 months, p < 0.001). Postoperative 90-day mortality was lower in the PDS group (1.7% vs. 2.4%, p < 0.001), though IDS patients had a lower 30-day readmission rate (6.2% vs. 3.1%, p < 0.001). IDS patients were less likely to undergo extensive surgery (27.4% vs. 36.7%, p < 0.001) and more likely to achieve R0 resection (42% vs. 38.6%, p < 0.001). The IDS rate increased from 18.9% to 40.6% (annual percentage change (APC): 11.8%, p < 0.05) from 2010 to 2017. Median OS improved from 46.6 to 51 months (APC: 1.9%, p < 0.05), driven by the PDS cohort. The R0 resection rate rose from 34.8 to 41% (APC: 2.65%, p < 0.01), driven by the PDS cohort (APC: 2.83%, p < 0.01). Postoperative 90-day mortality decreased from 2.4% to 1.5% (APC: −4.64%, p < 0.05), due to a reduction in PDS patients (APC: −6.83%, p < 0.05). There was no change in the rate of extensive surgery over time. In conclusion, from 2010 to 2017, increased triage of patients to NACT was accompanied by a higher R0 resection rate and reduced postoperative mortality in PDS patients, with no observed detriment to OS. This data suggests improvement in case selection between IDS and PDS. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Figure 1

11 pages, 599 KB

Open AccessArticle

Endometrial Intraepithelial Neoplasia, Concurrent Endometrial Cancer and Risk for Pelvic Sentinel Node Metastases

by Tabayi Hawez, Michele Bollino, Celine Lönnerfors and Jan Persson

Cancers 2024, 16(24), 4215; https://doi.org/10.3390/cancers16244215 - 18 Dec 2024

Cited by 3 | Viewed by 1836

Abstract

Background/objectives: Given the risk of a progression, or an undiagnosed endometrial cancer (EC), the treatment of choice is hysterectomy in women with endometrial intraepithelial neoplasia (EIN). The risk of metastatic disease and whether sentinel node (SLN) biopsy should be performed remains unclear. The primary aim of this prospective study was to determine the overall incidence of concurrent EC and the impact of the diagnostic tool used and the type of endometrial lesion. The secondary aim was to investigate the risk of metastatic SLNs. Methods: Between July 2019 and May 2024, 98 consecutive women with EIN deemed suitable for robotic surgery and SLN dissection were included in the study. Ultrastaging and immunohistochemistry were performed on all SLNs. Results: In total, 47% of women with preoperative EIN had EC on final histology; 13% of these had metastatic SLNs and the overall risk of metastases was 6.3%. Women who obtained their diagnosis by an endometrial biopsy had 65% risk of EC. All women with metastatic SLNs had non-polypoid lesions and five out of six obtained their diagnosis through endometrial biopsy. Conclusions: The overall risk of SLN metastases was 6.3%, all in women with a general endometrial thickening and/or a diagnosis of EIN by office endometrial biopsy, suggesting that SLN detection should be offered particularly to women with EIN who fulfill these preoperative criteria. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Figure 1

10 pages, 1415 KB

Open AccessArticle

Breast-Conserving Surgery Guided with Magnetic Seeds vs. Wires: A Single-Institution Experience

by Elisa Moreno-Palacios, Covadonga Martí, Laura Frías, Marcos Meléndez, Adolfo Loayza, María José Roca, Vicenta Córdoba, José María Oliver, Alicia Hernández and José Ignacio Sánchez-Méndez

Cancers 2024, 16(3), 566; https://doi.org/10.3390/cancers16030566 - 29 Jan 2024

Cited by 4 | Viewed by 2058

Abstract

Purpose: The aim of this study is to describe our initial experience using magnetic seeds (Magseed^®) to guide breast-conserving surgery in non-palpable breast lesions and compare the use of magnetic seed with wires to guide breast-conserving surgery in terms of clinical and pathological characteristics. Methods: We performed a retrospective study including all breast-conserving surgeries for non-palpable breast lesions under 16 mm from June 2018 to May 2021. We compared breast-conserving surgeries guided with magnetic seeds (Magseed^®) to those guided with wires, analyzing tumor and patient characteristics, surgical time, and pathological results of the surgical specimens. Results: Data from 225 cases were collected, including 149 cases guided by magnetic seeds and 76 cases guided by wires. The breast lesion was localized in every case. Both cohorts were similar regarding clinical and pathological characteristics. We found significant statistical differences (p < 0.02) in terms of the median volume (cm³) of the excised specimen, which was lower (29.3%) in the magnetic seed group compared with the wire group (32.5 [20.5–60.0]/46.0 [20.3–118.7]). We did not find significant differences regarding surgical time (min) or the affected or close margins. Conclusion: In our experience, the use of magnetic seed (Magseed^®) is a feasible option to guide breast-conserving surgery of non-palpable lesions and enabled us to resect less breast tissue. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Figure 1

12 pages, 443 KB

Open AccessArticle

Urinary, Gastrointestinal, and Sexual Dysfunctions after Chemotherapy, Radiotherapy, Radical Surgery or Multimodal Treatment in Women with Locally Advanced Cervical Cancer: A Multicenter Retrospective Study

by Mariano Catello Di Donna, Giuseppe Cucinella, Vincenzo Giallombardo, Giulio Sozzi, Nicolò Bizzarri, Giovanni Scambia, Basilio Pecorino, Paolo Scollo, Roberto Berretta, Vito Andrea Capozzi, Antonio Simone Laganà and Vito Chiantera

Cancers 2023, 15(24), 5734; https://doi.org/10.3390/cancers15245734 - 7 Dec 2023

Cited by 9 | Viewed by 2055

Abstract

Background: Different strategies have been proposed for the treatment of locally advanced cervical cancer (LACC), with different impacts on patient’s quality of life (QoL). This study aimed to analyze urinary, bowel, and sexual dysfunctions in a series of LACC patients who underwent chemotherapy, radiotherapy, radical surgery, or a combination of these treatments. Methods: Patients with LACC who underwent neoadjuvant radio–chemotherapy (NART/CT; n = 35), neoadjuvant chemotherapy (NACT; n = 17), exclusive radio–chemotherapy (ERT/CT; n = 28), or upfront surgery (UPS; n = 10) from November 2010 to September 2019 were identified from five oncological referral centers. A customized questionnaire was used for the valuation of urinary, gastrointestinal, and sexual dysfunctions. Results: A total of 90 patients were included. Increased urinary frequency (>8 times/day) was higher in ERT/CT compared with NACT/RT (57.1% vs. 28.6%; p = 0.02) and NACT (57.1% vs. 17.6%; p = 0.01). The use of sanitary pads for urinary leakage was higher in ERT/CT compared with NACT/RT (42.9% vs. 14.3%; p = 0.01) and NACT (42.9% vs. 11.8%; p = 0.03). The rate of reduced evacuations (<3 times a week) was less in UPS compared with NACT/RT (50% vs. 97.1%; p < 0.01), NACT (50% vs. 88.2, p < 0.01), and ERT/CT (50% vs. 96.4%; p < 0.01). A total of 52 women were not sexually active after therapy, and pain was the principal reason for the avoidance of sexual activity. Conclusions: The rate and severity of urinary, gastrointestinal, and sexual dysfunction were similar in the four groups of treatment. Nevertheless, ERT/CT was associated with worse sexual and urinary outcomes. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Figure 1

Other

Jump to: Research

48 pages, 1815 KB

Open AccessSystematic Review

Metastatic Carcinomas at the Episiotomy Site: A Systematic Literature Review

by Andrea Palicelli, Gabriele Tonni, Federica Torricelli, Beatrice Melli, Vincenza Ylenia Cusenza, Sandra Martinelli, Eleonora Zanetti, Alessandra Bisagni, Magda Zanelli, Maria Paola Bonasoni, Teresa Rossi, Lucia Mangone, Venus Damaris Medina-Illueca, Maurizio Zizzo, Andrea Morini, Giuseppe Broggi, Rosario Caltabiano, Serena Salzano, Francesca Sanguedolce, Nektarios I. Koufopoulos, Ioannis Boutas, Aleksandra Asaturova, Chiara Casartelli, Sara Rubagotti, Matteo Crotti, Lorenzo Aguzzoli and Vincenzo Dario Mandato Show full author list Hide full author list

Cancers 2025, 17(17), 2801; https://doi.org/10.3390/cancers17172801 - 27 Aug 2025

Viewed by 1072

Abstract

Background/Objectives: Rarely, primary (PriCs) or metastatic (metECs) carcinomas occur in the episiotomy site. Methods: A systematic literature review of metECs was carried out. We reviewed the PRISMA guidelines and the Scopus, Pubmed, and Web of Science databases. Results: We found 21 carcinomas; all of them were cervical carcinomas (11 squamous, SCC; 6 adenocarcinomas; 3 adenosquamous; 1 SCC or adenocarcinoma) diagnosed during pregnancy (38%) or 0.25–8 months postpartum (57%). SCCs were larger (mean size: 4.8 cm). At presentation, only two cases were pN+, and no distant metastases were found, excluding four episiotomy metastases (one anticipating the cervical cancer diagnosis); the remaining episiotomy metastases (mean size: 3 cm; one multifocal) were found at follow-up (these were first metastases in 86% of cases). The time range from the episiotomy/last delivery to first episiotomy metastasis was 1–66 (mean, 12.3) months. Treatment was variable: hysterectomy (71%) ± lymphadenectomy (67%) and/or adjuvant treatment (19%); chemoradiation/radiotherapy alone (24%). A total of 90% of cases recurred after 18 days to 66 months (mean, 12 months). At last follow-up, ten patients (48%) were disease-free after 12–120 (mean, 63.5) months, two patients (10%) were alive with disease, and nine (42%) patients died of disease after 6–36 (mean, 12.5) months (including two never-cleared/progressing cases). Conclusions: PriCs and metECs are rare. Iatrogenic/obstetric implantation or vascular dissemination of cervical cancer at the site of episiotomy may occur. For episiotomy lesions, accurate gynecological/perineal examination is required, and biopsy can be considered. Larger studies are required in order to determine treatment guidelines. Compared to PriCs, metECs occurred in younger (premenopausal) patients, were not associated with endometriosis, and demonstrated slightly smaller size and shorter mean time from episiotomy to episiotomy metastases, with a higher likelihood of a less favorable prognosis. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Figure 1

2 pages, 144 KB

Open AccessReply

Reply to Gücer, F.; Dünnebacke, J. Comment on “Hawez et al. Endometrial Intraepithelial Neoplasia, Concurrent Endometrial Cancer and Risk for Pelvic Sentinel Node Metastases. Cancers 2024, 16, 4215”

by Tabayi Hawez, Michele Bollino, Celine Lönnerfors and Jan Persson

Cancers 2025, 17(8), 1339; https://doi.org/10.3390/cancers17081339 - 16 Apr 2025

Viewed by 373

Abstract

We thank you for your interest in our paper and would like to comment on your reflections [...] Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

2 pages, 141 KB

Open AccessComment

Comment on Hawez et al. Endometrial Intraepithelial Neoplasia, Concurrent Endometrial Cancer and Risk for Pelvic Sentinel Node Metastases. Cancers 2024, 16, 4215

by Fatih Gücer and Jan Dünnebacke

Cancers 2025, 17(8), 1315; https://doi.org/10.3390/cancers17081315 - 14 Apr 2025

Cited by 1 | Viewed by 407

Abstract

We read with interest the recent paper by Hawez et al [...] Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

18 pages, 991 KB

Open AccessSystematic Review

Primary or Interval Debulking Surgery for Advanced Endometrial Cancer with Carcinosis: A Systematic Review and Individual Patient Data Meta-Analysis of Survival Outcomes

by Giulia Mantovani, Camelia Alexandra Coada, Stella Di Costanzo, Francesco Mezzapesa, Lucia Genovesi, Giorgio Bogani, Francesco Raspagliesi, Alessio Giuseppe Morganti, Pierandrea De Iaco and Anna Myriam Perrone

Cancers 2025, 17(6), 1026; https://doi.org/10.3390/cancers17061026 - 19 Mar 2025

Viewed by 1444

Abstract

Objective. To compare the survival outcomes of primary debulking surgery and platinum-based adjuvant chemotherapy versus interval debulking surgery after platinum-based neoadjuvant chemotherapy in patients with stage IVb endometrial cancer and peritoneal carcinosis. Methods. The online search included the following data sources: PubMed, Scopus, WOS, and the Cochrane Library from 1990 to 2024 (PROSPERO registration code: CRD42023438602). A total of 3230 studies were identified, with the inclusion of 16. Individual patient data on survival outcomes, disease distribution, and residual tumors, as well as details of neoadjuvant chemotherapy and adjuvant treatment, were extracted. Results. A total of 285 patients were included: 197 (69%) underwent primary debulking surgery and 88 (31%) underwent interval debulking surgery. The pooled analysis revealed a median progression-free survival in the primary debulking surgery group of 18.0 months compared to 12.0 months in the interval debulking surgery group (p = 0.028; log-rank test), and a median overall survival of 30.92 months versus 28.73 months (p = 0.400; log-rank test). Among the 134 patients with available information on the residual tumor after primary debulking surgery or interval debulking surgery, 110 (82%) had no macroscopic residual tumor (residual tumor = 0). The median progression-free survival was 18.9 months in the residual tumor = 0 group compared to 6.19 months in the residual tumor > 0 group (p < 0.001; log-rank test); the median overall survival was 40.6 months versus 21 months (p = 0.028; log-rank test). Conclusions. These results indicate that primary debulking surgery should be considered the preferred treatment approach for advanced endometrial cancer with carcinosis, especially in carefully selected patients where complete cytoreduction is achievable. Further prospective studies are warranted to confirm these results and to establish standardized criteria for patient selection, incorporating molecular-integrated risk profiles for endometrial cancer. Full article

(This article belongs to the Special Issue Advancements in Surgical Approaches for Gynecological Cancers)

► Show Figures

Journal Menu

Journal Browser

Advancements in Surgical Approaches for Gynecological Cancers

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (9 papers)

Research

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI